Henagan, Tara M., Stewart, Laura K., Forney, Laura A., Sparks, Lauren M., Johannsen, Neil, Church, Timothy S.
funding text
This work was supported by NIH NIDDK 5T32-DK064584-09 (Tara M. Henagan), NIH COBRE (8P20-GM103528-07), and NIH NIDDK DK068298 (Timothy S. Church).
abstract
PGC1 alpha, a transcriptional coactivator, interacts with PPARs and others to regulate skeletal muscle metabolism. PGC1 alpha undergoes splicing to produce several mRNA variants, with the NTPGC1 alpha variant having a similar biological function to the full length PGC1 alpha (FLPGC1 alpha). CVD is associated with obesity and T2D and a lower percentage of type 1 oxidative fibers and impaired mitochondrial function in skeletal muscle, characteristics determined by PGC1 alpha expression. PGC1 alpha expression is epigenetically regulated in skeletal muscle to determine mitochondrial adaptations, and epigenetic modifications may regulate mRNA splicing. We report in this paper that skeletal muscle PGC1 alpha - 1 nucleosome (-1N) position is associated with splice variant NTPGC1 alpha but not FLPGC1 alpha expression. Division of participants based on the -1N position revealed that those individuals with a -1N phased further upstream from the transcriptional start site (UP) expressed lower levels of NTPGC1 alpha than those with the -1N more proximal to TSS (DN). UP showed an increase in body fat percentage and serum total and LDL cholesterol. These findings suggest that the -1N may be a potential epigenetic regulator of NTPGC1 alpha splice variant expression, and -1N position and NTPGC1 alpha variant expression in skeletal muscle are linked to CVD risk. This trial is registered with clinicaltrials.gov, identifier NCT00458133.